In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

The biosimilar ocrelizumab candidate (Xacrel) was found to be equivalent to the originator product (Ocrevus) in reducing the annualized relapse rate and showed comparable safety and efficacy over 96 ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...